An Open-label Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)

Key Inclusion Criteria: * Able to provide full informed consent and comply with all requirements of the study protocol * Male or female participants ≥18 years old * Pathogenic or likely pathogenic mutation of LMNA * NYHA Class I, II, or III * Anti-AAV9 neutralizing antibody titer per protocol-specified criteria * Adequate hepatic and renal function per protocol-specified criteria Key Exclusion Criteria: * Any chronic medical condition that in the opinion of the Investigator would compromise the safety and/or compliance of the enrolled participant * Any clinically relevant change in standard of care heart failure medication prior to the Screening Visit * Any unstable cardiac symptoms requiring cardiac surgery, myocardial infarction, or percutaneous coronary intervention within 6 months prior to Screening * NYHA class IV or anticipated need for LVAD or transplant in the next 6 months * Pregnant or lactating or planning to become pregnant * Receiving an investigational intervention or participating in another clinical study within 30 days or within 5 half-lives of the drug prior to Screening * Prior participation in any gene therapy or approved gene therapy clinical study.